Neil Shah

20PUBLICATIONS
172CO-AUTHORS
Environmental epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|May 05, 2026
Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.

|Nov 02, 2025
Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes.

Heather Derry-Vick, Neil J Shah, Jaeil Ahn

|Oct 13, 2025
Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Neil J Shah, Reshma Shinde, Rituparna Bhattacharya

|Aug 29, 2025
Pragmatic Use of Minimal Common Oncology Data Elements and Observational Medical Outcomes Partnership at an Academic Medical Center.

Tatyana Sandler, Sarah Manglicmot, Katelyn M Mullen

|Jun 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.

Kathryn E Beckermann, Neil J Shah, Matthew T Campbell

|May 14, 2025
Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies.

Neil J Shah, Sneha Sura, Reshma Shinde

Pageof 4

Frequent Collaborators

4 joint publications

Robert J Motzer

4 joint publications

Maria Isabel Carlo

4 joint publications

Ritesh R Kotecha

3 joint publications

Michael B Atkins